tafamidis

This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III

Latest news

Alnylam claims first RNAi approval from FDA for patisiran

approved for that indication by the EMA in July and Pfizer’s Vyndaqel (tafamidis) which has been on the market since 2011 but was rejected by the FDA in 2012.
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The EMA said in a statement that having two drugs “considerably widens”the therapeutic options for hATTR amyloidosis, which include liver transplant, Pfizer’s Vyndaqel (tafamidis) and off-label non-steroidal
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The EMA said in a statement that having two drugs “considerably widens”the therapeutic options for hATTR amyloidosis, which include liver transplant, Pfizer’s Vyndaqel (tafamidis) and off-label non-steroidal
Pfizer drug gets speedy FDA review for rare heart failure complication

The average life expectancy for people with transthyretin cardiomyopathy is three to five years from diagnosis, says Pfizer, which also got fast-track status for tafamidis last year. ... Since then, tafamidis has also been approved in other markets
Pfizer’s flat sales focus investor attention on M&A

Vaccines for Clostridium difficile and staphylococcal infections and a new-generation Prevnar are making progress, along with rare disease therapies tafamidis for neuropathies and rivipansel for vaso-occlusive crises and tanezumab

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Director Healthcare PR Communications: Salary TBC

Editorial Director – Medical Education: Neg

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Team Lead: Competitive Salary

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Account Executive – Medical Communications: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Director – Head of Public Affairs: Neg

Account Director: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

Associate Medical Director: Highly Competitive

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Account Director - Digital: Great salary and benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Associate Medical Director: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Experienced Editor, London, Medical Communications: Competitive package

Subscribe to our email news alerts

PMHub

Add my company

SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...
Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...